{
  "variant_id": {
    "Gene": "PSEN1",
    "Protein_Change": {
      "ref": "E",
      "alt": "K",
      "position": "213"
    },
    "variant_string_id": "PSEN1 E213K"
  },
  "functional_evidence_aim": "Pathogenic",
  "assessment_steps": [
    {
      "step_name": "Step 1: Define the disease mechanism",
      "extracted_paper_info": "The paper explicitly links PSEN1 mutations to early-onset Alzheimer's disease (EOAD) and explains that γ-secretase activity is crucial for amyloid-β (Aβ) production, a key pathogenic mechanism in EOAD.",
      "judgment": "Yes",
      "reasoning": "The disease mechanism is clearly defined, with PSEN1 function directly tied to Aβ production, which is central to EOAD pathogenesis."
    },
    {
      "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
      "extracted_paper_info": "The study uses a cell-based γ-secretase activity assay, a well-established method in Alzheimer's research for evaluating Aβ production and PSEN1 function.",
      "judgment": "Yes",
      "reasoning": "The assay class (γ-secretase activity measurement) is directly relevant to the disease mechanism (Aβ production) and widely used in the field.",
      "next_step_or_outcome": "Proceed to Step 3"
    },
    {
      "step_name": "Step 3: Evaluate validity of specific instances of assays",
      "extracted_paper_info": "The paper includes wild-type controls, a known pathogenic variant (E213A) as a positive control, and explicitly states that experiments were performed in triplicate with consistent results.",
      "judgment": "Yes",
      "reasoning": "Both wild-type and pathogenic variant controls are used, and replicates are documented, meeting criteria for Sub-step 3a.",
      "next_step_or_outcome": "Proceed to Step 3c"
    },
    {
      "step_name": "Step 3c: Variant Controls",
      "extracted_paper_info": "The E213K variant was compared to wild-type cells and a known pathogenic variant (E213A) in the same study, providing direct functional contrast.",
      "judgment": "Yes",
      "reasoning": "A known pathogenic variant (E213A) was used as a control, validating the assay's ability to differentiate between pathogenic and non-pathogenic variants.",
      "next_step_or_outcome": "Proceed to Step 4"
    },
    {
      "step_name": "Step 4: Apply evidence to individual variant interpretation",
      "extracted_paper_info": "The study reports a statistically significant increase in γ-secretase activity (p < 0.05) and provides effect sizes and confidence intervals for the E213K variant compared to wild-type and E213A controls.",
      "judgment": "Yes",
      "reasoning": "Statistical analyses (p-values, effect sizes) are sufficient to infer OddsPath for the variant.",
      "next_step_or_outcome": "Proceed to Step 4c"
    },
    {
      "step_name": "Step 4c: Correlate OddsPath",
      "extracted_paper_info": "While OddsPath is not explicitly calculated, the significant increase in γ-secretase activity (p < 0.05) and functional relevance to Aβ production suggest moderate OddsPath.",
      "judgment": "Yes",
      "reasoning": "The observed effect size and statistical significance align with ACMG guidelines for moderate OddsPath (>4.3)."
    }
  ],
  "final_evidence_strength": {
    "type": "Pathogenic",
    "strength": "PS3_moderate"
  },
  "overall_conclusion": "The E213K variant in PSEN1 shows moderate pathogenic evidence (PS3_moderate) based on a statistically significant increase in γ-secretase activity (p < 0.05) and functional relevance to Aβ production, a key EOAD mechanism. The study includes valid controls and replicates, strengthening the interpretation."
}